Full-Time

Senior Clinical Operations Lead

Updated on 8/1/2026

Sarepta

Sarepta

1,001-5,000 employees

Develops gene therapies for rare diseases

Compensation Overview

$152.4k - $190.5k/yr

Cambridge, MA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Word/Pages/Docs
Quality Assurance (QA)
Google Cloud Platform
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Sarepta

See people who can refer or advise you

Requirements
  • Experience in management of contract research organizations, vendors, and consultants.
  • Proficient written and verbal communication skills.
  • Strong computer skills, including knowledge of Excel, Word, PowerPoint, Outlook, and Microsoft Project.
  • A Bachelor's degree in health sciences or a related field.
  • A minimum of 7+ years of experience in clinical research, including at least 4 years of experience in study management, with strong experience in Phase I-IV studies, global trials, and complex trial designs.
  • Candidates must be authorized to work in the United States.
Responsibilities
  • Manage all aspects of assigned clinical trials and the study project plan, including timelines, budgets, and vendors, and conduct large, highly complex studies.
  • Provide leadership and potentially line management within Clinical Operations and guidance regarding operational deliverables.
  • Oversee contract research organizations, vendors, and consultants involved with clinical trials.
  • Serve as the point of contact for protocol execution and lead the Clinical Trial Team.
  • Mentor junior team members and ensure alignment with supporting Clinical Operations Leads assigned to studies.
  • Establish study timelines in line with company goals and ensure accurate tracking and reporting of study metrics and progress through completion of study dashboards.
  • Work cross-functionally to ensure clinical program timelines and goals are met and risks are appropriately escalated to the Clinical Operations Program Lead.
  • Ensure trial adherence to International Council for Harmonisation, Good Clinical Practice, federal and local regulations, and company-specific standard operating procedures.
  • Develop, review, and consult on reports and clinical trial documents such as informed consent forms, clinical protocols, Investigator's Brochure, yearly updates to regulatory authorities, and status updates.
  • Communicate and escalate study-related issues to the Clinical Operations Program Lead.
  • Provide enrollment forecasting to internal stakeholders, such as Clinical Supply, at the agreed frequency.
  • Conduct routine completeness checks of the Trial Master File to ensure compliance with International Council for Harmonisation, Good Clinical Practice, and company standard operating procedures, and ensure all appropriate documents are filed.
  • Participate in and respond to Quality Assurance and regulatory authority inspection audits.
  • Facilitate development of trial budgets and execution of clinical trial agreements and other relevant documents in conjunction with contract research organizations and appropriate internal stakeholders.
  • Manage the clinical trial budget and provide financial reporting and projections to Finance.
  • Lead creation of scopes of work and budgets and escalate vendor performance issues to the Clinical Operations Program Lead and Procurement as necessary.
  • Participate in operational improvement initiatives, including standard operating procedure development and training.
Desired Qualifications
  • Documented training, knowledge, and application of current FDA/EU regulations, Good Clinical Practice, and International Council for Harmonisation guidelines for patient registries and studies.
  • Experience developing trial plans including site management, risk mitigation strategies, trial budgets, and program-level budgets.
  • Ability to collaborate effectively with the study team, cross-functional team members, and external partners, including investigators and site staff, using collaborative negotiation skills.
  • Position may require some travel.
  • Rare disease study management is recommended.

Sarepta Therapeutics focuses on developing precision genetic medicines to treat rare diseases. It specializes in Duchenne muscular dystrophy (DMD) and is advancing gene therapies for limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth disease, MPS IIIA, and other CNS disorders. The company conducts research and development, carries therapies through clinical trials, and seeks regulatory approvals to bring treatments to patients, earning revenue from approved therapies and strategic partnerships. Its goal is to speed up drug development from lab research to patient treatment and to build the world’s largest gene therapy manufacturing capacity to meet global demand.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1980

Get referred to Sarepta

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • EMBARK data shows 70 percent slower disease progression over three years in ambulatory DMD patients aged 4 to 7.
  • FDA accepted supplemental applications for AMONDYS 45 and VYONDYS 53, backed by ESSENCE study and 1,800 real-world patient cases.
  • 2025 revenue of $1.86 billion and $954 million cash provide liquidity for ELEVIDYS commercial reset and siRNA program advancement.

What critics are saying

  • Boxed warning for acute liver injury and fatal non-ambulatory deaths restricts ELEVIDYS to ambulatory patients, slashing treatable population by 40 to 50 percent.
  • FDA clinical hold on LGMD trials after three deaths and revocation of AAVrh74 platform designation blocks next-generation pipeline entirely.
  • CEO Ingram retirement by end-2026 amid two fatalities and 500 job cuts creates leadership vacuum during critical ELEVIDYS commercial reset.

What makes Sarepta unique

  • Only approved gene therapy for ambulatory Duchenne muscular dystrophy patients aged 4 and older.
  • Exon-skipping franchise with AMONDYS 45 and VYONDYS 53 undergoing traditional FDA approval conversion by February 2027.
  • Proprietary AAVrh74 platform advancing siRNA programs for DM1 and FSHD with proof-of-concept readouts expected Q1 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
Yahoo Finance
Mar 23rd, 2026
Sarepta seeks FDA approval conversion for AMONDYS 45 and VYONDYS 53 using ESSENCE Phase 3 data

Sarepta Therapeutics has received FDA agreement to file supplemental applications by end of April seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, using data from the ESSENCE Phase 3 study and real-world evidence in Duchenne muscular dystrophy. The regulatory conversion could validate Sarepta's exon-skipping platform and strengthen its DMD franchise durability. However, the company faces ongoing safety concerns around its gene therapy ELEVIDYS. Sarepta is enrolling non-ambulant patients to test an enhanced immunosuppression regimen, with primary endpoints focused on acute liver injury incidence. The company's narrative projects $1.4 billion revenue and $171.6 million earnings by 2028, implying 17% annual revenue decline. Most optimistic analysts forecast $713.6 million earnings on $1.9 billion revenue by 2028.

Yahoo Finance
Mar 3rd, 2026
Bavarian Nordic CEO steps down amid pharma leadership shake-up

Bavarian Nordic has announced that CEO Paul Chaplin will step down after 11 years leading the Danish vaccine specialist, marking the latest executive change in pharmaceuticals this year. Chaplin, who joined in 2014, is leaving for personal reasons as his family relocates to Australia. He will remain until year-end or until a successor is found. The move follows recent departures elsewhere. Sarepta's Doug Ingram announced his retirement last month after a decade as CEO, citing family health concerns. Sanofi revealed in February it would not renew Paul Hudson's contract after six years, with share prices falling over 20% since February 2025. Belén Garijo, currently CEO of Merck KGaA, will take over at Sanofi from 29 April.

Yahoo Finance
Mar 1st, 2026
Wells Fargo cuts Sarepta Therapeutics price target to $38 from $45 after GTx launch delays

Wells Fargo has cut its price target on Sarepta Therapeutics to $38 from $45, maintaining an Overweight rating. The firm adjusted its ELEVIDYS projections, noting the gene therapy launch reset following safety events may take longer than anticipated based on 2026 guidance. However, Wells Fargo expects positive results from the company's siRNA readout. Separately, Baird reduced its price target to $20 from $22 with a Neutral rating following Sarepta's fiscal 2025 results. The company reported full-year net product revenues of $1.864 billion, comprising $965.6 million from PMO products and $898.7 million from ELEVIDYS. Sarepta Therapeutics develops RNA-targeted therapeutics and gene therapy for rare diseases, with several approved treatments for Duchenne muscular dystrophy.

Yahoo Finance
Feb 26th, 2026
Sarepta Therapeutics CEO Ingram to retire after tumultuous year for gene therapy Elevidys

Sarepta Therapeutics CEO Douglas Ingram will retire by the end of 2026 or upon appointment of his successor, the company announced in a regulatory filing. The firm has begun searching for his replacement. Ingram's departure follows a turbulent 2025 for the biotech company. Its gene therapy Elevidys, used to treat a muscle disorder, was linked to two patient deaths, prompting the FDA to request voluntary shipment halts. The company cut 500 jobs and halted development of several gene therapies. Elevidys carries the FDA's most serious safety warning and requires stringent monitoring. Despite the setbacks, Ingram said on Wednesday the therapy is on a potential pathway for expanded use. Sarepta's shares fell 82% last year and were down 4% in after-market trading. Ingram has led the company since 2017.

Yahoo Finance
Feb 26th, 2026
Sarepta posts $1.86B revenue, guides $1.2B–$1.4B for 2026 as CEO plans retirement

Sarepta Therapeutics reported 2025 net product revenue of $1.86 billion, comprising $966 million from its PMO franchise and $899 million from ELEVIDYS. The company guided 2026 approved-therapy revenue between $1.2 billion and $1.4 billion, whilst ending 2025 with $954 million in cash. Management described 2026 as a commercial "critical reset" for ELEVIDYS following two fatal events in 2025. Clinically, EMBARK three-year data showed a statistically significant 4.39-point NSAA benefit and approximately 70–73% slowing on key functional measures. Proof-of-concept readouts for DM1 and FSHD siRNA programmes are expected by end-Q1, with a Huntington's trial to begin in H1 2026. CEO Doug Ingram announced plans to retire around end-2026, with the board conducting a comprehensive successor search.